Oxford Biomedica (LON:OXB) Releases Quarterly Earnings Results

Oxford Biomedica (LON:OXB) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported GBX (30.39) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative net margin of 23.23% and a negative return on equity of 54.51%.

Oxford Biomedica Trading Down 0.1%

Shares of OXB opened at GBX 480.50 on Thursday. The company has a debt-to-equity ratio of 273.08, a current ratio of 2.21 and a quick ratio of 1.67. Oxford Biomedica has a 1 year low of GBX 420 and a 1 year high of GBX 952. The company has a 50 day simple moving average of GBX 512.48 and a two-hundred day simple moving average of GBX 576.03. The firm has a market cap of £581.64 million, a P/E ratio of -17.85 and a beta of 1.09.

Oxford Biomedica News Summary

Here are the key news stories impacting Oxford Biomedica this week:

• Positive Sentiment: Client wins accelerated. Oxford Biomedica reported 17 new clients during the period, described as record commercial wins. The expanding customer base supports future manufacturing and development revenue. OXB wins 17 new clients as its expansion gathers pace
• Positive Sentiment: Revenue growth and guidance were maintained. First-half revenue reached £80.2 million, representing approximately 9% growth, while management maintained its full-year 2026 outlook. The client pipeline is also expected to improve revenue visibility. Oxford Biomedica H1 Revenue Reaches £80.2 Million as FY2026 Guidance Maintained
• Positive Sentiment: Technology partnership expands operational capabilities. Oxford Biomedica is deploying Veeva Quality Cloud as part of a global quality transformation. The move may improve quality-system efficiency and support the company’s growing international operations. Oxford Biomedica Advances Global Quality Transformation with Veeva Quality Cloud
• Neutral Sentiment: Veeva selected another major biopharmaceutical customer for Vault CRM. The announcement reinforces Veeva’s market position, but its direct impact on Oxford Biomedica is limited beyond the broader relationship between the companies. Veeva Systems Vault CRM Extends Market Leadership
• Negative Sentiment: Profitability remains the main concern. Oxford Biomedica reported a quarterly loss of GBX 30.39 per share, while its first-half loss widened. The company also reported a negative net margin and negative return on equity, leaving investors focused on the timing of a return to profitability. Oxford Biomedica earnings results

Wall Street Analyst Weigh In

OXB has been the subject of several analyst reports. Jefferies Financial Group reissued a “buy” rating and issued a GBX 8.27 target price on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 595 price objective on shares of Oxford Biomedica in a research report on Wednesday, September 2nd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a GBX 900 target price on shares of Oxford Biomedica in a report on Tuesday, September 1st. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 580.85.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.